Minhae Park
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Minhae Park has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Eunkyu Lee
Departments of Otorhinolaryngology-Head and Neck Surgery Samsung Medical Center Sungkyunkwan University School of Medicine 성균관대학교 의과대학 삼성서울병원 이비인후과학교실 Seoul Korea 하비갑
1 shared publication - Gwanghui Ryu
Department of Otorhinolaryngology-Head and Neck Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea
1 shared publication Hyo Yeol Kim
Department of Otorhinolaryngology-Head and Neck Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea
1 shared publication- Hyo Yeol Kim
Department of Otorhinolaryngology-Head and Neck Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea
1 shared publication - Sang Duk Hong
Department of Otorhinolaryngology‐Head and Neck Surgery Samsung Medical Center, Sungkyunkwan University School of Medicine Seoul Republic of Korea
1 shared publication - Song I Park
Department of Otorhinolaryngology-Head and Neck Surgery Ilsan Paik Hospital Inje University College of Medicine Goyang Republic of Korea
1 shared publication
Latest Publications
- 9 September 2023
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 62 (suppl 67) , PA2198
Late Breaking Abstract - Development of a Novel Scoring System to Predict Survival of Acute Invasive Fungal Rhinosinusitis Patients
Background: The article discusses acute invasive fungal rhinosinusitis (AIFR), a life-threatening disease that progresses rapidly despite appropriate treatment. The article aims to analyze the factors that impact overall survival (OS) and disease-specific survival (DSS) separately and develop a scoring system based on significant factors to facilitate counseling on prognosis and planning an appropriate treatment plan. Methods: We enrolled 120 patients with pathologically proven AIFR through reviewing data from the past 15 years at two tertiary referral hospitals. Disease-specific survival (DSS) and overall survival (OS) were calculated, and a statistically meaningful scoring system was developed. Results: The DSS rate of AIFR was 77.5% (93/120 cases), and the OS rate was 40.8% (49/120 cases). Multivariate analysis for DSS identified fungal invasion in the orbit and CRP levels greater than 6 (mg/dL) as significant factors, while underlying hematologic malignancy, ANC levels less than 500 (/μL), and CRP levels greater than 6 (mg/dL) were associated with OS. Conclusion: This study aimed to develop a nomogram to predict the prognosis of patients with AIFR using indicators such as orbit involvement and CRP levels above 6 mg/dL. The nomogram could assist medical professionals in evaluating a patient9s condition, predicting prognosis, and devising a treatment plan based on the results.
- 9 September 2023
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 62 (suppl 67) , PA2198
Late Breaking Abstract - Development of a Novel Scoring System to Predict Survival of Acute Invasive Fungal Rhinosinusitis Patients
Background: The article discusses acute invasive fungal rhinosinusitis (AIFR), a life-threatening disease that progresses rapidly despite appropriate treatment. The article aims to analyze the factors that impact overall survival (OS) and disease-specific survival (DSS) separately and develop a scoring system based on significant factors to facilitate counseling on prognosis and planning an appropriate treatment plan. Methods: We enrolled 120 patients with pathologically proven AIFR through reviewing data from the past 15 years at two tertiary referral hospitals. Disease-specific survival (DSS) and overall survival (OS) were calculated, and a statistically meaningful scoring system was developed. Results: The DSS rate of AIFR was 77.5% (93/120 cases), and the OS rate was 40.8% (49/120 cases). Multivariate analysis for DSS identified fungal invasion in the orbit and CRP levels greater than 6 (mg/dL) as significant factors, while underlying hematologic malignancy, ANC levels less than 500 (/μL), and CRP levels greater than 6 (mg/dL) were associated with OS. Conclusion: This study aimed to develop a nomogram to predict the prognosis of patients with AIFR using indicators such as orbit involvement and CRP levels above 6 mg/dL. The nomogram could assist medical professionals in evaluating a patient9s condition, predicting prognosis, and devising a treatment plan based on the results.
- Open Access
- 30 May 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (11) , 9489
The Mechanism of Action and Clinical Efficacy of Low-Dose Long-Term Macrolide Therapy in Chronic Rhinosinusitis
Various chronic inflammatory airway diseases can be treated with low-dose, long-term (LDLT) macrolide therapy. LDLT macrolides can be one of the therapeutic options for chronic rhinosinusitis (CRS) due to their immunomodulatory and anti-inflammatory actions. Currently, various immunomodulatory mechanisms of the LDLT macrolide treatment have been reported, as well as their antimicrobial properties. Several mechanisms have already been identified in CRS, including reduced cytokines such as interleukin (IL)-8, IL-6, IL-1β, tumor necrosis factor-α, transforming growth factor-β, inhibition of neutrophil recruitment, decreased mucus secretion, and increased mucociliary transport. Although some evidence of effectiveness for CRS has been published, the efficacy of this therapy has been inconsistent across clinical studies. LDLT macrolides are generally believed to act on the non-type 2 inflammatory endotype of CRS. However, the effectiveness of LDLT macrolide treatment in CRS is still controversial. Here, we reviewed the immunological mechanisms related to CRS in LDLT macrolide therapy and the treatment effects according to the clinical situation of CRS.
- 30 May 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (11) , 9489
Open AccessThe Mechanism of Action and Clinical Efficacy of Low-Dose Long-Term Macrolide Therapy in Chronic Rhinosinusitis
Various chronic inflammatory airway diseases can be treated with low-dose, long-term (LDLT) macrolide therapy. LDLT macrolides can be one of the therapeutic options for chronic rhinosinusitis (CRS) due to their immunomodulatory and anti-inflammatory actions. Currently, various immunomodulatory mechanisms of the LDLT macrolide treatment have been reported, as well as their antimicrobial properties. Several mechanisms have already been identified in CRS, including reduced cytokines such as interleukin (IL)-8, IL-6, IL-1β, tumor necrosis factor-α, transforming growth factor-β, inhibition of neutrophil recruitment, decreased mucus secretion, and increased mucociliary transport. Although some evidence of effectiveness for CRS has been published, the efficacy of this therapy has been inconsistent across clinical studies. LDLT macrolides are generally believed to act on the non-type 2 inflammatory endotype of CRS. However, the effectiveness of LDLT macrolide treatment in CRS is still controversial. Here, we reviewed the immunological mechanisms related to CRS in LDLT macrolide therapy and the treatment effects according to the clinical situation of CRS.